OVax®: A Feasibility Study Using a DNP-Modified Autologous Ovarian Tumor Cell Vaccine as Therapy in Ovarian Cancer Patients After Relapse:

NCT00660101 Phase 1/Phase 2 UNKNOWN

To determine if a vaccine made from the patient's own tumor tissue can stimulate an immune response against the patient's tumor cells. To determine the safety of the vaccine.

Details

Lead sponsor	AVAX Technologies
Phase	Phase 1/Phase 2
Status	UNKNOWN
Enrolment	34
Start date	2008-06
Completion	2016-01

Conditions

• Adenocarcinoma of the Ovary

Interventions

• OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine

Primary outcomes

• Cell-mediated immunity to autologous tumor cells — 3 months

Countries

United States